South Korea's Seegene develops PCR test to detect monkeypox virus
Several countries are stepping up vaccination and testing as monkeypox cases continue to climb
South Korean molecular diagnostics company Seegene has developed a PCR test to detect the monkeypox virus, as cases continue to emerge in countries where the disease is rarely seen.
The company used its AI-based automated test development system, known as SGDDS (Seegene Digitalized Development System), to create the Novaplex™ MPXV Assay. It specifically targets the monkeypox virus and can identify a positive case in 90 minutes.
Seegene plans to provide the assays to countries that have detected the virus.
More than 40 countries where monkeypox is not endemic have reported outbreaks of the viral disease as confirmed cases exceeded 4,300 this week. According to recent WHO data, the majority of monkeypox cases (86%) were detected in Europe, while the Americas recorded 11% and Africa recorded just 2%.
Geographical spread of monkeypox cases. Source: WHO.
Monkeypox is a typically mild viral infection that is endemic in parts of west and central Africa. It spreads through close contact and can be identified by flu-like symptoms, distinctive rashes and lesions on the skin. It has been spreading largely between men who have sex with men outside the countries where it is endemic, though it is not defined as a sexually transmitted infection.
The strain currently circulating in the Northern Hemisphere has an estimated fatality rate of between 3% and 6% and is considered especially dangerous for children and those with weak immune systems.
This week the White House outlined plans to distribute thousands of monkeypox vaccines and to increase nationwide testing. In their latest directive, the federal government called on anyone with possible monkeypox exposure to get vaccinated. Previously, the vaccines were only offered to people who have had a known exposure.
Earlier this month the European Commission placed an order with Danish biotech Bavarian Nordic for 110,000 doses of their Imvanex vaccine, which is currently only authorised for use against smallpox in the EU. The European Medicines Agency (EMA) has since initiated a review of Imvanex data with the intention of extending its use to include protection against monkeypox. European Commissioner for Health and Food Safety Stella Kyriakides announced that the first batch of vaccine deliveries were being shipped to member states with the highest case numbers.
Speaking on June 28, she announced: ‘As of today, the first deliveries of vaccines in response to the monkeypox outbreak are arriving to the most affected countries. This is a European Health Union that responds in real time to new health threats and protects its citizens. This is the first time that we are, through our Health Preparedness and Response Authority (HERA), directly buying and donating vaccines to Member States. With HERA up and running, the EU has significantly reinforced its capacity to respond and address new health threats decisively.’
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance